Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Nuvectis Pharma (NVCT)

December 3, 2025 6:44 AM EST Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $10.00 price target on Nuvectis Pharma (NASDAQ: NVCT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login